Jianmin Pharmaceutical Group Co.,Ltd. released its half-year report on August 19th.
According to the announcement, the company reported operating revenue of 1,804,599,192.51 yuan for the first half of the year, representing a 10.2% year-on-year decrease. Net profit attributable to shareholders of the listed company reached 220,625,625.18 yuan, down 7.83% compared to the same period last year.
The announcement also revealed that among the top ten circulating shareholders, Industrial and Commercial Bank of China - Rongtong Health Industry Flexible Allocation Hybrid Securities Investment Fund emerged as a new circulating shareholder.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments